» Articles » PMID: 35281633

Photothermal Ablation of Murine Melanomas by FeO Nanoparticle Clusters

Overview
Specialty Biotechnology
Date 2022 Mar 14
PMID 35281633
Authors
Affiliations
Soon will be listed here.
Abstract

Melanoma is one of the deadliest forms of cancer, for which therapeutic regimens are usually limited by the development of resistance. Here, we fabricated FeO nanoparticle clusters (NPCs), which have drawn widespread attention, and investigated their role in the treatment of melanoma by photothermal therapy (PTT). Scanning electron microscopy imaging shows that our synthesized NPCs are spherical with an average diameter of 329.2 nm. They are highly absorptive at the near-infrared wavelength of 808 nm and efficient at locally converting light into heat. In vitro experiments using light-field microscopy and cell viability assay showed that FeO NPCs, in conjunction with near-infrared irradiation, effectively ablated A375 melanoma cells by inducing overt apoptosis. Consistently, in vivo studies using BALB/c mice found that intratumoral administration of FeO NPCs and concomitant in situ exposure to near-infrared light significantly inhibited the growth of implanted tumor xenografts. Finally, we revealed, by experimental approaches including semi-quantitative PCR, western blot and immunohistochemistry, the heat shock protein HSP70 to be upregulated in response to PTT, suggesting this chaperone protein could be a plausible underlying mechanism for the observed therapeutic outcome. Altogether, our results highlight the promise of FeO NPCs as a new PTT option to treat melanoma.

Citing Articles

Nanoparticle-Based Treatment Approaches for Skin Cancer: A Systematic Review.

Diaz M, Natarelli N, Aflatooni S, Aleman S, Neelam S, Tran J Curr Oncol. 2023; 30(8):7112-7131.

PMID: 37622997 PMC: 10453819. DOI: 10.3390/curroncol30080516.


Advances in the Application of Nanomaterials to the Treatment of Melanoma.

Wang Z, Yu Y, Wang C, Li J, Pang Y Pharmaceutics. 2022; 14(10).

PMID: 36297527 PMC: 9610396. DOI: 10.3390/pharmaceutics14102090.

References
1.
Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

2.
Vostakolaei M, Hatami-Baroogh L, Babaei G, Molavi O, Kordi S, Abdolalizadeh J . Hsp70 in cancer: A double agent in the battle between survival and death. J Cell Physiol. 2020; 236(5):3420-3444. DOI: 10.1002/jcp.30132. View

3.
Estelrich J, Busquets M . Iron Oxide Nanoparticles in Photothermal Therapy. Molecules. 2018; 23(7). PMC: 6100614. DOI: 10.3390/molecules23071567. View

4.
Yu T, Li P, Tseng T, Chen Y . Multifunctional Fe₃O₄/alumina core/shell MNPs as photothermal agents for targeted hyperthermia of nosocomial and antibiotic-resistant bacteria. Nanomedicine (Lond). 2011; 6(8):1353-63. DOI: 10.2217/nnm.11.34. View

5.
Chu M, Shao Y, Peng J, Dai X, Li H, Wu Q . Near-infrared laser light mediated cancer therapy by photothermal effect of Fe3O4 magnetic nanoparticles. Biomaterials. 2013; 34(16):4078-4088. DOI: 10.1016/j.biomaterials.2013.01.086. View